For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231212:nRSL5349Wa&default-theme=true
RNS Number : 5349W Intuitive Investments Group plc 12 December 2023
12 December 2023
Intuitive Investments Group plc
("IIG" or the "Company")
The Company announces the issue and allotment of 2,687,095 ordinary shares of
1 penny each ("Ordinary Shares"), fully paid. These shares were issued for
cash at a price of 15.66 pence per share.
Application has been made for the new Ordinary Shares, which will rank equally
with the existing Ordinary Shares of the Company, to be admitted to trading on
Specialist Fund Segment of the Main Market, becoming effective in accordance
with the admission and disclosure standards of the London Stock Exchange. It
is expected that admission will become effective and dealings in Consideration
Shares will commence at 8:00 a.m. on or around 13 December 2023 ("Admission").
Following Admission, the Company's issued share capital will consist
of 2,001,076,279 Ordinary Shares. Since the Company currently holds no shares
in treasury, the total number of voting rights in the Company will
be 2,001,076,279. Shareholders may use this figure as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.
Intuitive Investments Group plc www.iigplc.com (http://www.iigplc.com/)
Sir Nigel Rudd, Non-Executive Chairman Via FTI Consulting
Robert Naylor, CEO
SP Angel Corporate Finance LLP - Financial Adviser +44 (0) 20 3470 0470
Jeff Keating / David Hignell / Kasia Brzozowska
FTI Consulting
Jamie Ricketts / Valerija Cymbal / Jemima Gurney IIG@fticonsulting.com (mailto:IIG@fticonsulting.com)
About Intuitive Investments Group plc
IIG is an investment company seeking to provide investors with exposure to a
portfolio concentrating on fast growing and/or high potential Life Sciences
and Technology businesses operating predominantly in the UK, continental
Europe, the US and APAC, utilising the Board's experience to seek to generate
capital growth over the long term for shareholders.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEELLFFXLLZFBE